%0 Journal Article %A CLEMENTINE PUECH %A NATHALIE PREVOT %A NATHALIE PEREK %T Gefitinib Inhibits Sodium Phosphate Co-transporter III Isoform 1 in a Model of Human Malignant Glioma %D 2014 %J Anticancer Research %P 6527-6535 %V 34 %N 11 %X Background: The purpose of the present was to investigate whether the in vitro effects of gefitinib, an EGFR tyrosine kinase inhibitor, may regulate the expression of type III sodium phosphate Na/Pi co-transporters in an in vitro glioma model. Materials and Methods: Proliferation studies, global native EGFR and phosphorylated EGFR expressions, phosphate transporter type III isoform 1(PiT1) expression and phosphate transport with 99mTc-(V)-DMSA radioligand were performed in G111 (grade II astrocytoma), U-87-MG (grade III astrocytoma) and G152 (grade IV glioblastoma) cells. Results: Cells treated with gefitinib showed a significant decrease in proliferation in relation to EGFR and p-EGFR expression. Gefitinib also produced a decrease in phosphate transport mediated PIT1 expression at both the RNA and protein levels. Conclusion: The link between gefitinib acting on the EGFR and PiT1 regulation in these cancer cell lines was herein shown. %U https://ar.iiarjournals.org/content/anticanres/34/11/6527.full.pdf